Accordingly, stratification methods based on histopathological or molecular characteristics are extensively implemented, such as traditional clinical prognostic factors [3] (T4 tumor; tumor perforation; bowel obstruction; poorly differentiated tumor; venous invasion; <12 lymph nodes examined) and RAS mutation as a well-established determinant of resistance to anti-EGFR therapy [4,5]. This evidence concerns the gene EGFR and neoplasm.